These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15102690)

  • 1. Clinical significance of dysadherin expression in gastric cancer patients.
    Shimada Y; Yamasaki S; Hashimoto Y; Ito T; Kawamura J; Soma T; Ino Y; Nakanishi Y; Sakamoto M; Hirohashi S; Imamura M
    Clin Cancer Res; 2004 Apr; 10(8):2818-23. PubMed ID: 15102690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of dysadherin and E-cadherin expression in differentiated-type gastric carcinoma with submucosal invasion.
    Maehata Y; Hirahashi M; Aishima S; Kishimoto J; Hirohashi S; Yao T; Takashima H; Tsuneyoshi M; Oda Y
    Hum Pathol; 2011 Apr; 42(4):558-67. PubMed ID: 21239043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma.
    Shimada Y; Hashimoto Y; Kan T; Kawamura J; Okumura T; Soma T; Kondo K; Teratani N; Watanabe G; Ino Y; Sakamoto M; Hirohashi S; Imamura M
    Oncology; 2004; 67(1):73-80. PubMed ID: 15459499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysadherin: expression and clinical significance in thyroid carcinoma.
    Sato H; Ino Y; Miura A; Abe Y; Sakai H; Ito K; Hirohashi S
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4407-12. PubMed ID: 12970317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of dysadherin and E-cadherin expression in patients with head and neck cancer treated by radiation therapy.
    Muramatsu H; Akimoto T; Maebayashi K; Kita M; Mitsuhashi N
    Anticancer Res; 2008; 28(6B):3859-64. PubMed ID: 19192641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to e-cadherin expression.
    Shimamura T; Sakamoto M; Ino Y; Sato Y; Shimada K; Kosuge T; Sekihara H; Hirohashi S
    J Clin Oncol; 2003 Feb; 21(4):659-67. PubMed ID: 12586803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of dysadherin expression in patients with non-small cell lung cancer.
    Tamura M; Ohta Y; Tsunezuka Y; Matsumoto I; Kawakami K; Oda M; Watanabe G
    J Thorac Cardiovasc Surg; 2005 Sep; 130(3):740-5. PubMed ID: 16153922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC.
    Ono K; Uramoto H; Hanagiri T
    Anticancer Res; 2010 Sep; 30(9):3273-8. PubMed ID: 20944097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of dysadherin and E-cadherin in the development of testicular tumours.
    Batistatou A; Scopa CD; Ravazoula P; Nakanishi Y; Peschos D; Agnantis NJ; Hirohashi S; Charalabopoulos KA
    Br J Cancer; 2005 Dec; 93(12):1382-7. PubMed ID: 16333245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the dysadherin and E-cadherin expression in primary lung cancer and metastatic sites.
    Mitselou A; Batistatou A; Nakanishi Y; Hirohashi S; Vougiouklakis T; Charalabopoulos K
    Histol Histopathol; 2010 Oct; 25(10):1257-67. PubMed ID: 20712010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance.
    Kyzas PA; Stefanou D; Batistatou A; Agnantis NJ; Nakanishi Y; Hirohashi S; Charalabopoulos K
    Am J Surg Pathol; 2006 Feb; 30(2):185-93. PubMed ID: 16434892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.
    Izumi T; Oda Y; Hasegawa T; Nakanishi Y; Kawai A; Sonobe H; Takahira T; Kobayashi C; Yamamoto H; Tamiya S; Hirohashi S; Iwamoto Y; Tsuneyoshi M
    Am J Surg Pathol; 2007 Jan; 31(1):85-94. PubMed ID: 17197923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells.
    Nam JS; Kang MJ; Suchar AM; Shimamura T; Kohn EA; Michalowska AM; Jordan VC; Hirohashi S; Wakefield LM
    Cancer Res; 2006 Jul; 66(14):7176-84. PubMed ID: 16849564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
    Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
    Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of dysadherin expression in advanced colorectal carcinoma.
    Aoki S; Shimamura T; Shibata T; Nakanishi Y; Moriya Y; Sato Y; Kitajima M; Sakamoto M; Hirohashi S
    Br J Cancer; 2003 Mar; 88(5):726-32. PubMed ID: 12618882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases.
    Nakanishi Y; Akimoto S; Sato Y; Kanai Y; Sakamoto M; Hirohashi S
    Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):323-8. PubMed ID: 15536331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin.
    Batistatou A; Charalabopoulos K; Nakanishi Y; Vagianos C; Hirohashi S; Agnantis NJ; Scopa CD
    Endocr Pathol; 2008; 19(3):197-202. PubMed ID: 18677652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.
    Batistatou A; Peschos D; Tsanou H; Charalabopoulos A; Nakanishi Y; Hirohashi S; Agnantis NJ; Charalabopoulos K
    Br J Cancer; 2007 May; 96(9):1404-8. PubMed ID: 17437014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion.
    Tsuiji H; Takasaki S; Sakamoto M; Irimura T; Hirohashi S
    Glycobiology; 2003 Jul; 13(7):521-7. PubMed ID: 12672699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis.
    Ino Y; Gotoh M; Sakamoto M; Tsukagoshi K; Hirohashi S
    Proc Natl Acad Sci U S A; 2002 Jan; 99(1):365-70. PubMed ID: 11756660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.